Print Nanoparticle Vaccine Carrying Bacterial Polysaccharide And Protein Antigens Induces Enhanced B- And T-Cell (Il-17) Immunity
Pneumococcus is a common organism causing invasive bacterial disease, especially in children < 2 years and elderly adults. Using nanoparticles in vaccine formulations allows for improved antigen stability and immunogenicity, but also targeted delivery and slow release. A nanoparticle vaccine consisting of pneumococcal polysaccharides (PnPs) and protein antigens (toxoids, surface proteins) has the potential to offer broader and enhanced protective immunity (antibody/cellular) against invasive pneumococcal disease and carriage/colonization. In partnership with PATH, Liquidia is developing a next generation multivalent nanoparticle polysaccharide protein vaccine for Streptococcus pneumoniae based on roll-to-roll PRINT technology. Specifically, a PRINT nanoparticle multivalent vaccine developed co-delivers 2 components – (i) key capsular polysaccharides (PnPs 1, 4, 5, 14, 6A, 19A, 23F) and (ii) pneumococcal carrier protein. Conjugation of antigens onto NPs can allow presentation of the immunogen to the immune systems in much the same way that it would be presented by the pathogen, leading to potent and specific antibody (IgG) and cellular (IL-17) immune responses against target antigens.
Preclinical vaccination studies in mice and rabbits with single and multivalent non-adjuvanted PRINT formulations produced polysaccharide-specific functional antibody (IgG and OPK) responses greater than or equivalent to Prevnar-13. Additionally, existing PRINT particle formulations were translated to all of Prevnar-13 serotypes and multiple proteins (CRM197, pneumococcal specific surface proteins and toxoids, TT), further demonstrating the wide-ranging multi-antigen formulation capability.
Antigenic multivalent PRINT nanoparticle formulations leverage precise control of size, shape and composition, sterile filterability and scalable cGMP roll-to roll manufacturing to offering a low cost and simplified manufacturing advantage over traditional conjugate vaccines. Moreover, the broad flexibility of the current PRINT approach has been applied to other antigen targets such as typhoid, and H. influenzae. The expectation is that PRINT particulate vaccines will provide potent antigen-specific humoral and cellular immune responses and will allow development of next generation vaccines against a range of infectious diseases.
Preclinical vaccination studies in mice and rabbits with single and multivalent non-adjuvanted PRINT formulations produced polysaccharide-specific functional antibody (IgG and OPK) responses greater than or equivalent to Prevnar-13. Additionally, existing PRINT particle formulations were translated to all of Prevnar-13 serotypes and multiple proteins (CRM197, pneumococcal specific surface proteins and toxoids, TT), further demonstrating the wide-ranging multi-antigen formulation capability.
Antigenic multivalent PRINT nanoparticle formulations leverage precise control of size, shape and composition, sterile filterability and scalable cGMP roll-to roll manufacturing to offering a low cost and simplified manufacturing advantage over traditional conjugate vaccines. Moreover, the broad flexibility of the current PRINT approach has been applied to other antigen targets such as typhoid, and H. influenzae. The expectation is that PRINT particulate vaccines will provide potent antigen-specific humoral and cellular immune responses and will allow development of next generation vaccines against a range of infectious diseases.
